8-K: Mangoceuticals Secures $600,000 in Financing Through Preferred Stock and Promissory Note

Mangoceuticals, Inc. announces the completion of a $100,000 Series B Preferred Stock sale and a $500,000 promissory note to bolster its financial position.

Summary

• Mangoceuticals, Inc. entered into a Securities Purchase Agreement on April 11, 2025, selling 100 shares of Series B Convertible Preferred Stock for $100,000 to an institutional accredited investor.
• The agreement grants the purchaser participation rights in future financings for 18 months, up to the amount of their initial subscription, on the same terms as those future financings.
• On April 15, 2025, the company borrowed $500,000 from Indigo Capital LP, evidenced by a promissory note with an 18% annual interest rate, compounded monthly.
• The promissory note matures on April 15, 2026, or earlier upon an event of default or a qualified funding.
• Prepayment of the promissory note requires a premium equal to the interest that would have accrued until the stated maturity date.
• Events of default trigger an automatic increase in the outstanding amount to include a default amount equivalent to the interest that would have accrued until the stated maturity date.
• The sale of Series B Preferred Stock was exempt from registration under Section 4(a)(2) and/or Rule 506 of Regulation D of the Securities Act.
• If the Series B Preferred Stock shares sold on April 11, 2025, were converted in full, a maximum of 73,333 shares of common stock would be due to the holders thereof, based on a Conversion Price of $1.50 per share.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The company secured funding, which is positive, but the high interest rate on the promissory note and potential dilution from preferred stock conversion are concerns.

Positives

• The financing provides Mangoceuticals with additional capital for marketing, inventory, and working capital.
• The Securities Purchase Agreement includes customary representations, warranties, and covenants, offering some protection to the company.
• The company retains the option to prepay the promissory note, albeit with a premium.
• The investor in the Series B Preferred Stock has the right to participate in future financings.

Negatives

• The promissory note carries a high interest rate of 18% per annum.
• The promissory note includes a prepayment premium, increasing the cost of early repayment.
• Events of default trigger an automatic increase in the outstanding amount of the promissory note.
• The purchaser has the right to participate in any issuance by the Company or any of its subsidiaries of common stock or common stock equivalents or any offering of debt or any other type of financing, or a combination thereof (other certain customary exempt issuances)(each a Subsequent Financing ), in an amount not to exceed the amount of the Purchasers subscription, on the same terms, conditions and price provided for in the Subsequent Financing.

Risks

• Failure to meet payment obligations on the promissory note could lead to acceleration and increased costs due to default provisions.
• The company's ability to secure qualified funding is crucial for managing the promissory note's maturity.
• The conversion of Series B Preferred Stock could dilute existing shareholders' equity.
• The company is restricted from entering into any variable rate transaction for a period of 180 days from the closing date of the SPA.

Future Outlook

The company intends to use the net proceeds from the sale of the Securities hereunder for marketing expenditures, inventory purchases, and other working capital purposes.

Industry Context

Many small cap companies use preferred stock and promissory notes to raise capital. The 18% interest rate is high, but not uncommon for companies with limited access to capital markets.

Comparison to Industry Standards

• Comparable companies in the pharmaceutical or nutraceutical space often utilize similar financing methods, such as private placements of preferred stock and debt financing, to fund operations and growth initiatives.
• The terms of the promissory note, including the interest rate and prepayment provisions, are within the typical range for similar financings in the microcap market, but on the higher end.
• The participation rights granted to the purchaser in future financings are a common feature in private equity deals, allowing investors to maintain their ownership stake and benefit from future growth.

Stakeholder Impact

• Shareholders may experience dilution if the Series B Preferred Stock is converted to common stock.
• The financing provides the company with resources to potentially grow the business, which could benefit employees and other stakeholders.
• Creditors now include the purchaser of the preferred stock and Indigo Capital LP.

Next Steps

• The company will use the proceeds for marketing, inventory, and working capital.
• The company must adhere to the terms of the Securities Purchase Agreement and the Promissory Note.
• The company needs to apply for the listing of common stock issuable upon conversion of the Shares and the Warrant Shares on the Trading Market.

Key Dates

Keywords

financing, promissory note, preferred stock, securities purchase agreement, capital raise, mangoceuticals, debt, equity